This letter from the Kidney Care Partners (KCP) provides the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) with a set of principles that KCP hopes the Committee will take into account when considering the evidence related to the use of erythropoiesis-stimulating agents (ESAs) for treatment of anemia in adults with chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.
